Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGAV | P06756 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL854528 | 1.00 | SLC7A5 (0.42) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL21507745 | 0.91 | ALDH1A1 (0.39) | ALOX15ALDH1A1MEN1LMNAMAPT | |
| SCHEMBL1932929 | 0.85 | ALDH1A1 (0.36) | ALOX15ALDH1A1MEN1LMNAMAPT | |
| SCHEMBL1932933 | 0.85 | POLB (0.38) | ITGB3ITGAVALOX15ALDH1A1MEN1 | |
| SCHEMBL24324961 | 0.81 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2MEN1KMT2AUSP2 | |
| SCHEMBL23470065 | 0.80 | ALDH1A1 (0.38) | ALDH1A1MEN1LMNAMAPTKMT2A | |
| SCHEMBL18986854 | 0.80 | SLC7A5 (0.42) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL21507742 | 0.78 | GNRHR (0.35) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL20578136 | 0.75 | CA2 (0.43) | ALDH1A1TDP1LMNAHDAC3HDAC1 | |
| SCHEMBL6575751 | 0.75 | KMT2A (0.62) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3110828-B1 | CONTINUOUS FLOW PEPTIDE SYNTHESIS | UNIV SZEGEDI (HU) | 2020-12-09 | — | — | EP | claimed |
| EP-3110828-A1 | CONTINUOUS FLOW PEPTIDE SYNTHESIS | Szegedi Tudományegyetem (HU) | 2017-01-04 | — | — | EP | claimed |
| WO-2015128687-A1 | CONTINUOUS FLOW PEPTIDE SYNTHESIS | Szegedi Tudományegyetem (HU) | 2015-09-03 | — | — | WO | claimed |
| EP-2076535-B1 | RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS | SALK INST FOR BIOLOGICAL STUDI (US) | 2013-03-06 | — | — | EP | claimed |
| US-12486302-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2025-12-02 | — | — | US | disclosed |
| EP-4630064-A1 | ALPHA EMITTER LABELLED SOMATOSTATIN RECEPTOR ANTAGONISTS | Ariceum Therapeutics GmbH (DE) | 2025-10-15 | — | — | EP | disclosed |
| US-20250235566-A1 | TRISLINKER-CONJUGATED DIMERIC LABELING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM | Medianezia GmbH (DE) | 2025-07-24 | — | — | US | disclosed |
| US-20250222146-A1 | Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof | RAYZEBIO, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| WO-2025137443-A1 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING SOMATOSTATIN RECEPTORS AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025137441-A1 | RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-118785925-A | Marker precursors and radiotracers with three or more targeting vectors for use in diagnostic nuclear medicine therapies | 原子治疗有限公司 | 2024-10-15 | — | — | CN | disclosed |
| WO-2024121249-A1 | ALPHA EMITTER LABELLED SOMATOSTATIN RECEPTOR ANTAGONISTS | ARICEUM THERAPEUTICS GMBH (DE) | 2024-06-13 | — | — | WO | disclosed |
| EP-2383289-A1 | Receptor (SSTR2)-selective somatostatin antagonists | The Salk Institute for Biological Studies (US) | 2011-11-02 | — | — | EP | disclosed |
| US-7960342-B2 | Side effect reduction; block receptor function so they can be used in therapy; labeled with radioactive iodine; drug screening | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2011-06-14 | — | — | US | disclosed |
| EP-2268667-A2 | SOMATOSTATIN RECEPTOR 2 ANTAGONISTS | Salk Institute For Biological Studies (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009129311-A2 | SOMATOSTATIN RECEPTOR 2 ANTAGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2009-10-22 | — | — | WO | disclosed |
| EP-2076535-A2 | RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20080299040-A1 | SOMATOSTATIN RECEPTOR 2 ANTAGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES UNIVERSITAT BERN UNIVERSITY HOSPITAL BASEL | 2008-12-04 | — | — | US | disclosed |
| US-20080260638-A1 | RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008048942-A2 | RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260638-A1 | RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS | SSTR5, SSTR4, SSTR3 | SLC7A5 85/4885PTGS1 4381/4885ALPI 4180/4885 |
| US-12486302-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | SLC7A5 1032/4885PTGS1 2711/4885ALPI 918/4885 |
| US-20250235566-A1 | TRISLINKER-CONJUGATED DIMERIC LABELING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM | TK1, TK2, TMT1A | SLC7A5 357/4885PTGS1 4069/4885ALPI 4643/4885 |
| US-20250222146-A1 | Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof | SSTR2, SSTR4, SSTR5 | SLC7A5 286/4885PTGS1 4839/4885ALPI 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.